Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RAD21_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RAD21_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RAD21_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RAD21_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RAD21_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RAD21_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RAD21_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RAD21_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RAD21_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200125222 | Oral cavity | EOLP | positive regulation of chromosome organization | 23/2218 | 82/18723 | 5.42e-05 | 7.00e-04 | 23 |
GO:000734621 | Oral cavity | EOLP | regulation of mitotic cell cycle | 82/2218 | 457/18723 | 7.50e-05 | 9.14e-04 | 82 |
GO:000706412 | Oral cavity | EOLP | mitotic sister chromatid cohesion | 11/2218 | 28/18723 | 1.96e-04 | 2.00e-03 | 11 |
GO:000706211 | Oral cavity | EOLP | sister chromatid cohesion | 18/2218 | 62/18723 | 2.12e-04 | 2.12e-03 | 18 |
GO:190199021 | Oral cavity | EOLP | regulation of mitotic cell cycle phase transition | 54/2218 | 299/18723 | 1.01e-03 | 7.54e-03 | 54 |
GO:004578721 | Oral cavity | EOLP | positive regulation of cell cycle | 56/2218 | 313/18723 | 1.04e-03 | 7.66e-03 | 56 |
GO:00063022 | Oral cavity | EOLP | double-strand break repair | 44/2218 | 251/18723 | 4.94e-03 | 2.62e-02 | 44 |
GO:00008192 | Oral cavity | EOLP | sister chromatid segregation | 36/2218 | 202/18723 | 7.92e-03 | 3.76e-02 | 36 |
GO:00519831 | Oral cavity | EOLP | regulation of chromosome segregation | 19/2218 | 91/18723 | 9.46e-03 | 4.29e-02 | 19 |
GO:20012511 | Oral cavity | EOLP | negative regulation of chromosome organization | 18/2218 | 86/18723 | 1.11e-02 | 4.88e-02 | 18 |
GO:200125214 | Prostate | BPH | positive regulation of chromosome organization | 34/3107 | 82/18723 | 8.14e-08 | 2.05e-06 | 34 |
GO:00447727 | Prostate | BPH | mitotic cell cycle phase transition | 112/3107 | 424/18723 | 1.57e-07 | 3.58e-06 | 112 |
GO:00073468 | Prostate | BPH | regulation of mitotic cell cycle | 115/3107 | 457/18723 | 1.52e-06 | 2.62e-05 | 115 |
GO:00330447 | Prostate | BPH | regulation of chromosome organization | 56/3107 | 187/18723 | 3.78e-06 | 5.81e-05 | 56 |
GO:00457878 | Prostate | BPH | positive regulation of cell cycle | 81/3107 | 313/18723 | 1.76e-05 | 2.18e-04 | 81 |
GO:19019904 | Prostate | BPH | regulation of mitotic cell cycle phase transition | 77/3107 | 299/18723 | 3.36e-05 | 3.77e-04 | 77 |
GO:001063916 | Prostate | BPH | negative regulation of organelle organization | 87/3107 | 348/18723 | 3.56e-05 | 3.90e-04 | 87 |
GO:00457863 | Prostate | BPH | negative regulation of cell cycle | 91/3107 | 385/18723 | 2.10e-04 | 1.71e-03 | 91 |
GO:00459303 | Prostate | BPH | negative regulation of mitotic cell cycle | 60/3107 | 235/18723 | 3.00e-04 | 2.32e-03 | 60 |
GO:19019874 | Prostate | BPH | regulation of cell cycle phase transition | 89/3107 | 390/18723 | 8.17e-04 | 5.34e-03 | 89 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAD21 | SNV | Missense_Mutation | | c.1522G>C | p.Glu508Gln | p.E508Q | O60216 | protein_coding | tolerated(0.18) | probably_damaging(0.932) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RAD21 | SNV | Missense_Mutation | novel | c.1627N>T | p.Asp543Tyr | p.D543Y | O60216 | protein_coding | tolerated(0.06) | possibly_damaging(0.67) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RAD21 | SNV | Missense_Mutation | | c.121N>C | p.Val41Leu | p.V41L | O60216 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.268N>T | p.Arg90Trp | p.R90W | O60216 | protein_coding | deleterious(0) | benign(0.167) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1485N>T | p.Glu495Asp | p.E495D | O60216 | protein_coding | tolerated(0.4) | benign(0.005) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RAD21 | SNV | Missense_Mutation | | c.1130N>G | p.Ala377Gly | p.A377G | O60216 | protein_coding | tolerated(0.25) | probably_damaging(0.978) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
RAD21 | insertion | Nonsense_Mutation | novel | c.1641_1642insAGAAGAATAAATTCTAAGTCTTAAACAACAACCTCAAT | p.Asp548ArgfsTer8 | p.D548Rfs*8 | O60216 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.185N>A | p.Gly62Glu | p.G62E | O60216 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | | c.1450N>C | p.Asp484His | p.D484H | O60216 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RAD21 | SNV | Missense_Mutation | novel | c.426N>C | p.Glu142Asp | p.E142D | O60216 | protein_coding | tolerated(0.15) | probably_damaging(0.956) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |